Overview

Efficacy and Safety of the Pain Relieving Effect of Dronabinol in Central Neuropathic Pain Related to Multiple Sclerosis

Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine whether Dronabinol is effective and safe in relieving central neuropathic pain in multiple sclerosis patients.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Bionorica Research GmbH
Treatments:
Dronabinol
Criteria
Inclusion Criteria:

- Diagnosis of multiple sclerosis acc. to McDonald diagnostic criteria

- EDSS score between 3 and 8 (incl.)

- Patients who are in a stable phase of multiple sclerosis

- Patients with MS-related central neuropathic pain for at least 3 months

Exclusion Criteria:

- Severe concomitant diseases

- Certain concomitant therapies (in particular: pain influencing concomitant therapies)

- Dronabinol intake within the last 12 months prior to study entry or Marihuana use
within one month prior to study entry